Finance

Lists
Q2 2026 earnings • released • Revenue beat +6.49%
See results
1SAN:BIT
Sanofi SA
€74.06
+1.73%
(+1.26) 1D
Jul 31, 5:29:43 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1SAN...
Open
€74.49
High
€75.18
Low
€74.06
Mkt. cap
91.35B
Avg. vol.
2.70K
Volume
8.35K
P/E ratio
11.98
52-wk high
€93.00
52-wk low
€71.27
EPS
€6.18
No. of employees
75K
Open
€74.49
High
€75.18
Low
€74.06
Mkt. cap
91.35B
Avg. vol.
2.70K
Volume
8.35K
P/E ratio
11.98
52-wk high
€93.00
52-wk low
€71.27
EPS
€6.18
No. of employees
75K
News stories
From sources across the web
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOPaul Hudson | Belén Garijo
Employees74.8K
Founded1973
HeadquartersParis, ÃŽle-de-France, France
SectorPharmaceutical industry
Websitesanofi.com
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
- / €1.90
Revenue / Est. (EUR)
11.60B / 10.89B
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
10.74B
13.17B
12.20B
11.24B
Cost of goods sold
2.99B
3.41B
3.63B
3.06B
Cost of revenue
2.99B
3.41B
3.63B
3.06B
Research and development expenses
1.91B
1.83B
2.29B
1.75B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.32B
2.29B
2.82B
2.33B
Operating expense
6.03B
5.97B
6.84B
5.94B
Total operating expenses
9.02B
9.39B
10.46B
9.00B
Operating income
1.71B
3.78B
1.74B
2.25B
Other non operating income
-24.00M
-
122.00M
-40.00M
EBT including unusual items
1.47B
3.51B
-1.16B
2.01B
EBT excluding unusual items
1.74B
3.67B
1.70B
2.14B
Income tax expense
230.00M
680.00M
-348.00M
420.00M
Effective tax rate
15.68%
19.38%
30.13%
20.85%
Other operating expenses
1.42B
1.39B
1.19B
1.33B
Net income
3.94B
2.80B
-801.00M
1.61B
Net profit margin
36.70%
21.28%
-6.56%
14.35%
Earnings per share
-
-
1.53
1.88
Interest and investment income
72.00M
114.00M
79.00M
60.00M
Interest expense
-62.00M
-227.00M
-
-138.00M
Net interest expenses
10.00M
-113.00M
79.00M
-78.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.48B
4.20B
3.49B
2.78B
Gain or loss from assets sale
-266.00M
266.00M
-79.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps